Skip to main content

CORRECTION article

Front. Public Health, 26 July 2022
Sec. Health Economics
Volume 10 - 2022 | https://doi.org/10.3389/fpubh.2022.965798

Corrigendum: Cost-effectiveness of avelumab maintenance therapy plus best supportive care vs. best supportive care alone for advanced or metastatic urothelial carcinoma

This article is a correction to:

  1. Cost-Effectiveness of Avelumab Maintenance Therapy Plus Best Supportive Care vs. Best Supportive Care Alone for Advanced or Metastatic Urothelial Carcinoma

    1. Read original article
\nQian XieQian Xie1Hanrui ZhengHanrui Zheng2Ye Chen Ye Chen1*Xingchen Peng Xingchen Peng1*
  • 1West China Hospital, Sichuan University, Chengdu, China
  • 2West China School of Medicine, West China Hospital, Sichuan University, Chengdu, China

A corrigendum on
Cost-Effectiveness of Avelumab Maintenance Therapy Plus Best Supportive Care vs. Best Supportive Care Alone for Advanced or Metastatic Urothelial Carcinoma

by Xie Q, Zheng H, Chen Y, and Peng X (2022). Front. Public Health 10:837854. doi: 10.3389/fpubh.2022.837854

In the published article, there was an error in Figure 2 where parts 2A and 2C were duplicated in parts 2B and 2D. The caption should also read as “The original Kaplan-Meier PFS and OS curves from the trial and fitted curves (Weibull distributions). OS, overall survival; PFS, progression-free survival.” The corrected figure appears below.

FIGURE 2
www.frontiersin.org

Figure 2. (A,B) The original Kaplan-Meier PFS and OS curves from the trial and fitted curves (Weibull distributions). OS, overall survival; PFS, progression-free survival.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: programmed cell death ligand 1, avelumab, cost-effective, advanced or metastatic urothelial cancer, maintenance therapy

Citation: Xie Q, Zheng H, Chen Y and Peng X (2022) Corrigendum: Cost-effectiveness of avelumab maintenance therapy plus best supportive care vs. best supportive care alone for advanced or metastatic urothelial carcinoma. Front. Public Health 10:965798. doi: 10.3389/fpubh.2022.965798

Received: 10 June 2022; Accepted: 12 July 2022;
Published: 26 July 2022.

Edited and reviewed by: Mihajlo Jakovljevic, Hosei University, Japan

Copyright © 2022 Xie, Zheng, Chen and Peng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Ye Chen, aHVheGljaGVueWVAMTYzLmNvbQ==; Xingchen Peng, cHh4MjAxNEAxNjMuY29t

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.